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RESEARCH ARTICLE
Growth Differentiation Factor 15 as a
Useful Biomarker for Mitochondrial
Disorders
Shuichi Yatsuga, MD, PhD,1 Yasunori Fujita, PhD,2 Akiko Ishii, MD, PhD,3
Yoshihiro Fukumoto, MD, PhD,4 Hajime Arahata, MD, PhD,5
Tatsuyuki Kakuma, PhD,6 Toshio Kojima, MD, PhD,7 Masafumi Ito, PhD,2
Masashi Tanaka, MD, PhD,8 Reo Saiki, MD,1 and Yasutoshi Koga, MD, PhD1
Objective: The diagnosis of mitochondrial disorders (MDs) is occasionally difficult because patients often present
with solitary, or a combination of, symptoms caused by each organ insufficiency, which may be the result of respira-
tory chain enzyme deficiency. Growth differentiation factor 15 (GDF-15) has been reported to be elevated in serum
of patients with MDs. In this study, we investigated whether GDF-15 is a more useful biomarker for MDs than several
conventional biomarkers.
Methods: We measured the serum levels of GDF-15 and fibroblast growth factor 21 (FGF-21), as well as other bio-
markers, in 48 MD patients and in 146 healthy controls in Japan. GDF-15 and FGF-21 concentrations were measured
by enzyme-linked immunosorbant assay and compared with lactate, pyruvate, creatine kinase, and the lactate-to-
pyruvate ratio. We calculated sensitivity and specificity and also evaluated the correlation based on two rating scales,
including the Newcastle Mitochondrial Disease Rating Scale (NMDAS).
Results: Mean GDF-15 concentration was 6-fold higher in MD patients compared to healthy controls (2,711 6 2,459
pg/ml vs 462.5 6 141.0 pg/mL; p < 0.001). Using a receiver operating characteristic curve, the area under the curve
was significantly higher for GDF-15 than FGF-21 and other conventional biomarkers. Our date suggest that GDF-15
is the most useful biomarker for MDs of the biomarkers examined, and it is associated with MD severity.
Interpretation: Our results suggest that measurement of GDF-15 is the most useful first-line test to indicate the
patients who have the mitochondrial respiratory chain deficiency.
ANN NEUROL 2015;78:814–823
Mitochondrial disorders (MDs) are occasionally diffi-cult to diagnose because patients present with one
or a combination of symptoms, such as psychomotor
developmental delay, failure to thrive, short stature, seiz-
ures, muscle weakness, hearing loss, heart failure, renal
failure, or diabetes. Because the plasma levels of lactate
and pyruvate are not always accurate biomarkers or MD
diagnosis, a novel biomarker, which is more sensitive, spe-
cific, reproducible, and quantitative, is required. Minimiz-
ing the number of specimens examined for MD diagnosis
is a very important issue for clinicians and/or diagnostic
centers in terms of cost- and time-effectiveness.
No reliable biomarker was available for the screen-
ing or diagnosis of MDs until 2011.1 Because an MD
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may present as “any symptom in any organ at any age,”2
we must develop an optionally useful biomarker for MD
diagnosis and the evaluation of therapeutic efficacy. In
2011, serum fibroblast growth factor 21 (FGF-21) was
reported to be a useful biomarker for the screening and
diagnosis of muscle-manifested MDs.3,4 The proposed
diagnostic process for MDs is as follows: (1) clinical
assessment; (2) measurement of the FGF-21 level; (3)
long-range polymerase chain reaction, next-generation
sequencing, or whole-exome sequencing of nuclear DNA;
and (4) with/without histopathological and biochemical
analysis via muscle biopsy, which may indicate approxi-
mately 70% to 80% of clinically suspected MDs.5 FGF-
21 appears to be a useful novel biomarker for the specific
screening of MDs because the measurement of FGF-21
involves a less-invasive approach than muscle biopsy.
Growth differentiation factor 15 (GDF-15) is a
member of the transforming growth factor beta super-
family. Expression of GDF-15 in nearly all tissues sug-
gests its general importance in essential cellular functions.
GDF-15 has been proposed as a biomarker of heart
disease, kidney disease, and cancers; however, its exact
biological functions remain poorly understood. It is
hypothesized that GDF-15 is elevated by activating tran-
scription factor 4 (ATF4), which is a stress-responsive
gene induced by various stresses.6 GDF-15 is currently
under investigation as a marker of the clinical risk fac-
tors, mortality, morbidity, and effectiveness of treatments
for heart disease, kidney disease, and some cancers; how-
ever, GDF-15 does not appear to play a useful role as a
diagnostic marker.7 In 2014, Kalko et al investigated the
gene expression profile of TK2-deficient human skeletal
muscle using complementary DNA microarrays and
demonstrated that serum GDF-15 (GDF-15) may be a
novel biomarker for MDs.8 We performed a microarray
analysis of 2SD cybrid cells that harbor a mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS)-causing mutation and control cells and dem-
onstrated that expression and secretion of GDF-15 were
increased in 2SD cells loaded by lactate; these findings
suggest that GDF-15 may serve as a useful marker for
MD diagnosis and evaluation of the therapeutic efficacy
FIGURE 1: STARD flow diagram and demography of the controls, MD patients, and disease controls. (A) All 48 MD patients
who fulfilled the clinical diagnostic criteria (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes [MELAS];
mitochondrial encephalopathy, and lactic acidosis [MELA], for which the main symptom was muscle weakness; Leigh syndrome
[LS]; overlapping MELAS/LS; and Kearns-Sayre syndrome [KSS]) and carried a known genetic abnormality were enrolled in this
study from 2005 to 2013. (B) Healthy adult and child volunteers without treatment or ambulatory medical care were also
recruited in 146 Japanese. MD 5 mitochondrial disorder; STARD 5 standards for reporting of diagnostic accuracy.
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of drugs.6 In this study, we measured GDF-15 concentra-
tions from patients who suffered from MDs, disease con-
trols, and healthy controls, and evaluated its usefulness
for MD diagnosis.
Patients and Methods
Participants
All MD patients who fulfilled the clinical diagnostic criteria
(MELAS; mitochondrial encephalopathy, and lactic acidosis
[MELA], for which the main symptom was muscle weakness;
Leigh syndrome [LS]; overlapping MELAS/LS; and Kearns-
Sayre syndrome [KSS]) and carried a known genetic abnormal-
ity were enrolled in this study from 2005 to 2013 (Fig 1A).
DNA, enzyme, or muscle histopathological analyses were per-
formed on all patients (Supplementary Table 1). The disease
controls consisted of adult and child patients with non-MD,
including 6 defined Duchenne muscular dystrophy (DMD), 9
multiple sclerosis (MS), 4 anti-AQP4 (aquaporin 4) antibody-
positive optic neuritis, 10 limbic encephalitis (anti-GluR [gluta-
mate receptor] antibody-positive, anti-NMDA [N-methyl-D-
aspartate] receptor-positive, varicella zoster virus infection, and
lung cancer), 1 brainstem encephalitis, 1 meningoencephalitis,
1 SLE (systemic lupus erythematosus) with CNS (central nerv-
ous system), 1 NMO (neuromyelitis optica), 1 HUS (hemolytic
uremic syndrome) encephalitis, and 8 defined heart failure
(HF) patients. All DMD patients were diagnosed with a large
deletion of the dystrophin gene by multiplex ligation-dependent
probe amplification (MLPA). All MS, optic neuritis, limbic
encephalitis, brainstem encephalitis, meningoencephalitis,
NMO, and HUS encephalitis patients were diagnosed with ful-
filled criteria. All HF patients were diagnosed based on an ejec-
tion fraction (EF) below 50% in this study (Supplementary
Table 1). Healthy adult and child volunteers without treatment
or ambulatory medical care were also recruited from Kurume
University Hospital, Fukuoka, Japan (Fig 1B). Mean age, BMI,
and % males are shown in Table 1. The study protocol was
approved by the institutional review boards of all centers (coor-
dinator: Kurume University Hospital, #13099). Written
informed consent was obtained from all subjects before
enrollment.
For the healthy controls, we calculated the body mass
index (BMI: kg/m2) of each individual and recruited healthy
adults (20 years old) who exhibited a BMI between 18 and
25 and children (<20 years old) who exhibited a BMI within
6 2 standard deviations (SDs) of the average for each age in
the Japanese population.
Procedures
The serum samples used in this study were collected for analysis
from 2012 to 2014. All samples were stored at –808C until
analysis. We measured the GDF-15 (R&D Systems, Minneapo-
lis, USA) and FGF-21 (FGF-21; BioVendor, Brno, Czech
Republic) concentrations in duplicate samples by enzyme-linked
immunorbent assay (ELISA). The samples for which the con-
centration of GDF-15 or FGF-21 was higher than the range of
detection were diluted 10-fold with dilution buffer and reana-
lysed. The value from each assay was compared with reference
GDF-15 and FGF-21 concentrations. We also measured the
levels of conventional biomarkers, such as lactate, pyruvate, the
lactate/pyruvate (L/P) ratio, and creatine kinase (CK). In addi-
tion, we recorded the height, body weight, BMI, and blood
sugar levels. The results of each assay were compared with a lin-
ear calibration curve. All assays were performed by a trained sci-
entist (S.Y. and R.S.).
The enrolled MD patients were clinically evaluated for
disease severity using two rating systems: the Japanese Mito-
chondrial Disease Rating Scale (JMDRS)9 and the Newcastle
Mitochondrial Disease Rating Scale (NMDAS).10 All scores
were also evaluated with respect to the levels of GDF-15 or
FGF-21 using correlation coefficients.
Statistical Analysis
The diagnostic test for MD using GDF-15 was evaluated by
receive operating characteristic (ROC) curve analyses. The
threshold value was determined using the Youden index.
Ninety-five percent confidence intervals (95% CIs) for the area
TABLE 1. Demographics of the Number, Mean Age, Mean BMI, and % Males for MD Patients and Non-MD
Patients
Controls MD Patients Disease Controls
Number 146 48 42
Age, years 23.6 6 13.7 33.6 6 18.7** 41.4 6 17.2***
BMI, kg/m2 (n) 19.1 6 3.0 (146) 17.4 6 3.3 (48)*** 21.7 6 3.8 (41)***
% males (n) 48.0 (70) 48.0 (23) 54.7 (23)
Mean age was significantly higher in MDs patients (33.6 6 18.7 years old; p < 0.01) and disease controls (41.4 6 17.2 years
old; p < 0.001) than in healthy controls (23.6 6 13.7 years old). Mean BMI was significantly lower in MDs patients (17.4 6
3.3 kg/m2; p < 0.001) than in healthy controls (19.1 6 3.0 kg/m2) and higher in disease controls (21.7 6 3.8 kg/m2; p <
0.001) than in healthy controls (19.1 6 3.0 kg/m2). Mann–Whitney U test: **p < 0.01; ***p < 0.001.
BMI 5 body mass index; MD 5 mitochondrial disorder.
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under the curve (AUC) of the ROC were obtained. Leave-one-
out cross-validation of GDF-15 and FGF-21 was performed.
Sensitivity and specificity of GDF-15 were compared with a
measurement of FGF-21 using a McNemar test. Comparison
of two correlated nonparametric AUCs was also performed.11
Spearman correlation coefficients were used to examine the
associations between the biomarkers.
Role of the Funding Source
This work was supported, in part, by grant nos. 25461571 (to
Y.K.), 25860891 (to S.Y.), and 25242062 (to M.T.) from the
Ministry of Education, Culture, Sports, Science and Technology
(MEXT) and by Grant-in-Aid no. 24-Nanchi-Ippan-005
(to Y.K.) for Research on Intractable Diseases from the Ministry
of Health, Labor and Welfare of Japan.
All patients and control individuals had perceived
adequate information concerning to this study according to the
guidelines of the Declaration of Helsinki.
Results
We analyzed samples from 48 patients who fulfilled the
clinicopathological and genetic criteria of MD. Of these
48 MD patients, 27 patients suffered from MELAS and
carried the m.3243A>G mutation in mitochondrial
DNA (mtDNA), with the exception of 3 patients whose
TABLE 2. JMDRS and NMDAS Scores for Each Mitochondrial Disorder
N JMDRS Range NMDAS Range
MELAS 12 30.3 6 17.7 4–60 36.0 6 2 3.4 8–82
MELA 11 9.9 6 9.4 0–27 12.6 6 8.3 0–24
KSS 3 26.0 6 18.4 5–39 45.7 6 18.9 25–62
Overlapping MELAS/LS 2 15.0 6 7.1 10–20 48.5 6 10.1 41–56
LS 3 67.0 6 15.7 56–85 94.7 6 19.9 72–103
JMDRS 5 Japanese Mitochondrial Disease Rating Scale; KSS 5 Kearns-Sayre syndrome; LS 5 Leigh syndrome; MELA 5 mito-
chondrial encephalopathy, lactic acidosis (mitochondrial myopathy); MELAS 5 mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes; NMDAS 5 Newcastle Mitochondrial Disease Rating Scale.
FIGURE 2: All biomarker concentrations for MDs and controls, and demography between MDs and non-MDs patients. (A) GDF-
15, (B) FGF-21, (C) lactate:pyruvate ratio, (D) lactate, (E) pyruvate, and (F) CK. MD patients exhibited significantly higher levels
of all biomarkers compared to controls. CK 5 creatine kinase; FGF-21 5 fibroblast growth factor 21; GDF-15 5 growth differ-
entiation factor 15; MD 5 mitochondrial disorder.
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molecular defects had not been identified. Eleven patients
suffered from MELA and carried the m.3243A>G muta-
tion. Three patients were diagnosed as LS, including 1
patient who exhibited a cytochrome c oxidase deficiency,
1 patient who carried the m.3243A>G mutation, and 1
patient who carried the m.8993T>C mutation. Two
patients suffered from overlapping MELAS/LS and car-
ried the m.3243A>G mutation, and 5 patients suffered
from KSS and carried a common large deletion in
mtDNA. The demographic characteristics of the patients
in this study are shown in Table 1. We also recruited
149 healthy controls; however, 3 individuals were
excluded because of abnormal thyroid function (Fig. 1B).
We evaluated the severity of each patient using two
rating systems, the JMDRS9 and the NMDAS,10 as
shown in Supplementary Table 1. The JMDRS has been
used in a Japanese MELAS cohort study and has been
demonstrated to be useful for the evaluation of disease
progression at 5-year intervals.9 Mean scores of MD
patients on the JMDRS and the NMDAS are shown in
Table 2.
The concentrations of GDF-15 and FGF-21 did
not differ by age, sex, or diurnal variation.12 The mean
concentration of GDF-15 and FGF-21 is shown in
Supplementary Table 2. The concentration range of
GDF-15 in the MD patients was substantially higher
compared to the controls. GDF-15 concentration did
not overlap between MD patients and controls; however,
FGF-21 concentration occasionally overlapped. In con-
trast, the GDF-15 reference range in healthy controls
was markedly narrow, as shown in Figure 2. GDF-15
concentration was higher in HF patients compared to
controls; however, FGF-21 was not different between the
HF patients and controls. GDF-15 and FGF-21 concen-
trations were not significantly different between the
DMD, the MS, optic neuritis, limbic encephalitis
patients, and controls (Fig 3).
Among the various MD subtypes, GDF-15 and
FGF-21 concentrations were the highest in LS and were
10-fold higher than controls. GDF-15 and FGF-21
concentrations in MELAS and MELA patients displayed
broad distributions. GDF-15 and FGF-21 concentra-
tions in KSS patients tended to be lower compared to
LS, MELAS, and MELA patients; however, they were
significantly higher than the controls (Supplementary
Table 2).
The correlation coefficients between the concentra-
tions of GDF-15 and FGF-21 and the JMDRS and
NMDAS were positively correlated (GDF-15: r 5 0.76
[p < 0.001] for the JMDRS and r 5 0.67 [p < 0.001]
FIGURE 3: Comparison of biomarkers for MDs, and GDF-15 and FGF-21 concentrations for MDs and non-MDs. GDF-15 and
FGF-21 concentrations in the patients who suffered from MD subtypes, DMD, MS, optic neuritis, limbic encephalitis, brain-
stem encephalitis, menigoencephalitis, SLE with CNS, NMO, and HUS encephalitis, and HF, and the control group are shown.
Each MD subtype displayed significantly higher levels of GDF-15 and FGF-21 than the control group. HF displayed signifi-
cantly higher levels of only GDF-15 than the control group. (A) GDF-15 and (B) FGF-21. CNS 5 central nervous system; DMD
5 Duchenne muscular dystrophy; FGF-21 5 fibroblast growth factor 21; GDF-15 5 growth differentiation factor 15; HUS 5
hemolytic uremic syndrome; KSS 5 Kearns-Sayre syndrome; LS 5 Leigh syndrome; MD 5 mitochondrial disorder; MS 5 multi-
ple sclerosis; MELA 5 mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); MELAS 5 mitochondrial ence-
phalopathy, lactic acidosis, and stroke-like episodes; NMO 5 neuromyelitis optica; SLE 5 systemic lupus erythematosus.
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for the NMDAS; FGF-21: r 5 0.69 [p < 0.001] for the
JMDRS and r 5 0.59 [p < 0.001] for the NMDAS), as
shown in Figure 4. The concentration of GDF-15 and
FGF-21 were positively correlated (r 5 0.64; p <
0.001), as shown in Figure 5.
AUC analyses indicated that the sensitivity and
specificity were significantly larger for GDF-15 than
those for FGF-21, lactate, pyruvate, the L/P ratio, or
CK. The AUC was 0.997 (95% CI: 0.993–1.000) for
GDF-15, 0.889 (95% CI: 0.837–0.962) for FGF-21,
FIGURE 4: Correlation coefficients between levels of GDF-15 and FGF-21 and the JMDRS and NMDAS. GDF-15 and FGF-21
levels were positively correlated with the JMDRS and NMDAS: GDF-15: r 5 0.76 (A: p < 0.001) for the JMDRS and r 5 0.67
(B: p < 0.001) for the NMDAS; FGF-21: r 5 0.69 (C: p < 0.001) for the JMDRS and r 5 0.59 (D: p < 0.001) for the NMDAS.
Spearman correlation coefficients were calculated for the statistical analysis. FGF-21 5 fibroblast growth factor 21; GDF-15 5
growth differentiation factor 15; JMDRS 5 Japanese Mitochondrial Disease Rating Scale; KSS 5 Kearns-Sayre syndrome; LS 5
Leigh syndrome; MELA 5 mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); NMDAS 5 Newcastle Mito-
chondrial Disease Adult Scale.
FIGURE 5: Correlation between GDF-15 and FGF-21 for
MDs. GDF-15 and FGF-21 levels were positively correlated
for mitochondrial disorders (MDs): r 5 0.64 (p < 0.001).
Spearman correlation coefficients were calculated for the
statistical analysis. FGF-21 5 fibroblast growth factor 21;
GDF-15 5 growth differentiation factor 15.
FIGURE 6: ROC curves for each biomarker in the MD
patients. AUC values were 0.997 (95% confidence interval
[CI]: 0.993–1.000) for GDF-15, 0.919 (95% CI: 0.865–0.973)
for the lactate-to-pyruvate ratio, 0.889 (95% CI: 0.837–
0.962) for FGF-21, 0.882 (95% CI: 0.814–0.950) for lactate,
0.706 (95% CI: 0.614–0.798) for pyruvate, and 0.609 (95%
CI: 0.506–0.711) for creatine kinase (CK). AUC 5 area under
the curve; FGF-21 5 fibroblast growth factor 21; GDF-15 5
growth differentiation factor 15; L/P ratio 5 lactate-to-
pyruvate ratio; MD 5 mitochondrial disorder; ROC 5
receiver operating characteristic.
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0.919 (95% CI: 0.865–0.973) for the L/P ratio, 0.882
(95% CI: 0.814–0.950) for lactate, 0.706 (95% CI:
0.614–0.798) for pyruvate, and 0.609 (95% CI: 0.506–
0.711) for CK (Fig 6). Two correlated nonparametric
AUCs were compared based on statistical analysis.11
AUC for GDF-15 (0.997; standard error [SE] 5 0.002)
was significantly larger (p 5 0.002) than in FGF-21
(0.899; SE 5 0.032) (difference: 0.098; Z-test: 3.07;
Pr >jZj: 0.002).
Based on our statistical analysis, we identified a
threshold value of 710.0 pg/mL GDF-15 to diagnose
MDs. For FGF-21, we also identified a threshold value of
350.0 pg/mL FGF-21 to diagnose MDs. The threshold
values for each biomarker were defined based on the cen-
tral laboratory results as follows: 1.9 mmol/L lactate,
106.8 lmol/L pyruvate, L/P ratio of 30, and CK depend-
ing on the age group, as described in Supplementary Table
3. We identified a distribution of abnormal values of those
biomarkers. Based on this analysis, sensitivities of GDF-15
and FGF-21 were 97.9% and 77.1%, respectively (p 5
0.0063) and specificities of GDF-15 and FGF-21 were
95.2% and 87.7%, respectively (p 5 0.0266). We tested
cross-validation for GDF-15 and FGF-21. The cross-
validated sensitivity and 1-specificity for both biomarkers
(N 5 194) were the following: The error rates (propor-
tion of incorrectly classified sample) of GDF-15 were 4.6
6 21.1% and FGF-21 was 14.9 6 35.7%.
The mean level and range of GDF-15 in the con-
trols are shown in Figure 7: a: 390 (SD not described;
N 5 29) pg/mL13; b: 267 6 91.2 (N 5 30) pg/mL14; c:
380.5 6 160 (N 5 37) pg/mL8; d: 463 (SD not
described; N 5 40) pg/mL15; e: 858.98 6 431.45 (N 5
21) pg/mL16; f: 276 6 251 (N 5 17) pg/mL17; g:
501 6 183 (N 5 31) pg/mL18; h: 540.09 (SD not
described; N 5 50) pg/mL.19 Our data of the mean level
and range of GDF-15 show as i: 462.5 6 141.0 (N 5
146) pg/mL.
The ID number, mean age, mean BMI, and %
males for the controls, MD patients, and disease controls
are presented in Table 1 and Supplementary Table 1.
Discussion
In this study, we have shown that GDF-15 appears to
serve as a sensitive and specific biomarker for the diagno-
sis and/or the monitoring of disease progression of MDs
in adults and children. GDF-15 exhibited greater sensi-
tivity and specificity than FGF-21. FGF-21 has been
reported to be a useful biomarker for muscle-manifesting
MDs3; however, there were many overlapping values
between controls and MD patients in our data. Because
a moderate increase in FGF-21 concentration has been
reported in a cachexic child with progeria,3 further inves-
tigation is required to investigate the specific conditions
that induce FGF-21 secretion. GDF-15 has also been
reported to be a useful biomarker for monitoring the
state of HF, renal failure, and certain cancers. The con-
founding factors that modulate the concentrations of
GDF-15 and FGF-21 remain to be identified. When
non-MD patients were complicated with HF and/or
renal failure, the concentration of GDF-15 was elevated
in the range of lower values of those observed in MD
patients without heart and/or renal failure. However, we
can distinguish easily between non-MD patients with HF
and/or renal failure, and MDs without those complica-
tion, by the information of clinical findings and labora-
tory data, such as creatinine, blood urea nitrogen, and
brain natriuretic peptide. On the other hand, diseases for
similar clinical manifestations with MDs, such as DMD,
MS, optic neuritis, and limbic encephalitis, are often dif-
ficult to distinguish from MDs even using routine labo-
ratory data. In these clinical conditions, we believe that
we can distinguish MD patients from patients with MD-
like symptoms by evaluation of GDF-15.
In general, LS is clinically recognized as the most
severe phenotype of the MD subtypes examined in this
study because LS patients typically die before 10 years of
age. According to both scaling system scores, LS dis-
played the highest scores of all examined MD subtypes.
The mean level of GDF-15 in LS patients was the high-
est of all MD patients. All LS patients in this study were
in a bed-ridden state, whereas the clinically diagnosed
MELAS patients exhibited a variety of disease severities
FIGURE 7: GDF-15 concentrations in the healthy controls
reported from literatures. GDF-15 concentrations were
recruited from literatures measured by the same ELISA kit
(R&D Systems, Minneapolis, MN), that are a13, b14, c8, d15,
e16, f17, g18, h19, and i (our data). Data are shown in mean
6 standard deviation (SD). References of a13, d15, and h19
are not described in SD. The number in parenthesis shows
sample number. Our GDF-15 level in the healthy controls
was similar to previous literatures.8,13–19 GDF-15 5 growth
differentiation factor 15.
ANNALS of Neurology
820 Volume 78, No. 5
that ranged from normal function, easy fatigability, severe
myopathy with sensorineural hearing loss, and diabetes
mellitus to bed-ridden (terminal stage). On the other
hand, we believe that MELA and KSS patients typically
maintain normal or subnormal states with respect to the
activities of daily living compared with LS and MELAS
patients.
The correlations between the JMDRS and NMDAS
scores and the GDF-15 and FGF-21 concentrations are
shown in Figure 4. The scores according to both scale
systems were the highest for LS; these scores are strongly
influenced by clinical severity, and LS displayed the most
severe phenotype in our study. The LS patients in our
study were bed-ridden and tube-fed. In contrast, the
scores for MELAS patients were highly variable for both
scales and were lower than those for LS, but higher than
those for KSS and MELA. The clinical scores of MELAS
Patients 17 and 18, who were in the bed-ridden stage,
were high on both the JMDRS and the NMDAS, which
is consistent with the levels of GDF-15 and FGF-21.
The overlapping MELAS/LS patients displayed highly
variable scores among individuals. Thus, GDF-15 and
FGF-21 may serve as quantitative biomarkers.
These results demonstrate that GDF-15 is the most
useful biomarker for MDs compared with FGF-21, lac-
tate, pyruvate, the L/P ratio, and CK. GDF-15 may serve
as a useful tool to quantitatively monitor disease severity
of our indexed MD subtypes.
GDF-15 is a more useful biomarker for muscle-
related MDs because of its substantially higher sensitivity
and specificity than FGF-21 and other conventional bio-
markers. FGF-21 was the best biomarker for muscle-
manifested MDs, as reported in 2011.3 We originally
used FGF-21 as a primary screening test for MDs; how-
ever, it was occasionally difficult to distinguish MD
patients from non-MD individuals based on FGF-21 val-
ues because the reference range of FGF-21 was broad. In
contrast, the reference range of GDF-15 was narrow and
rarely overlapped between MD patients and non-MD
individuals (Fig 2). Our reference range of GDF-15 was
in accord with previous studies (Fig 7). GDF-15 may be
especially useful for the diagnosis of LS and KSS because
serum lactate is rarely elevated in these MDs.1 The pres-
ent results revealed that GDF-15 was significantly ele-
vated in MD patients, which is consistent with our
recent report.6
GDF-15 appeared to increase with the clinical
severity of the MD (Fig 4). In general, MD severity is
ranked in the following order: LS, overlapping MELAS/
LS, MELAS, KSS, and MELA. In our study, mean
GDF-15 levels were ranked in the following order: LS,
MELAS, KSS, overlapping MELAS/LS, and MELA.
These results suggest that GDF-15 may serve as a useful
biomarker not only for the diagnosis, but also the deter-
mination of severity of MDs. GDF-15 may be poten-
tially as useful as FGF-21 for the evaluation of drug
efficacy; however, it should be verified by longitudinal
studies in future.
The AUC was significantly larger for GDF-15
(0.997) compared with the conventional MD bio-
markers, including FGF-21 (Fig 5). Our study demon-
strated that the AUC was also larger for FGF-21 (0.889)
compared with the other conventional MD biomarkers;
however, the AUC was slightly larger for the L/P ratio
(0.917) than for FGF-21 (0.889). The AUC for the L/P
ratio (0.917) was within the 95% CI of a previous study
(0.82–0.98).3 The AUC for sFGF-21 (0.889) was not
within the 95% CI of a previous study (0.94–0.99).3
The calculated threshold values of GDF-15 and FGF-21
were 707.0 and 343.8 pg/mL, respectively. We evaluated
the threshold values of 710.0 and 350.0 pg/mL for
GDF-15 and FGF-21, respectively. The sensitivity and
specificity of GDF-15 were 97.9% and 95.2%, respec-
tively, and were substantially higher than FGF-21, which
were 77.1% and 87.7%, respectively. Ultimately, GDF-
15 was a more useful biomarker than FGF-21 whether
we used our or other threshold values. The AUC was
higher for FGF-21 than for the L/P ratio in a previous
study3; however, the AUC was comparable between
FGF-21 and the L/P ratio in our study. We hypothesized
that these differences in the AUC for FGF-21 were
because of the different MDs and ages. Our MD patients
were primarily typical and classical, and the FGF-21 lev-
els may be lower in our study than in the previous
study.3 However, the patients in the previous study were
classified as MELAS, Alpers syndrome, MIRAS, and
others; moreover, 26 of the 67 (38.8%) MD patients
were children.3 In our study, 12 of the 48 (25%) MD
patients were children. The child MD patients exhibited
higher FGF-21 levels in both our study (LS and
MELAS/LS overlapping) and the previous study (Alpers
syndrome and patients with mtDNA mutations).3 Fur-
ther assessment of the various MD subtypes is required.
On the other hand, GDF-15 in HF patients was
significantly elevated compared to controls as well as
MDs. However, FGF-21 in HF patients was not signifi-
cantly elevated with controls. It is indicated that only
GDF-15 does not completely distinguish HF with MDs
from HF without MDs. We calculated that GDF-15 and
FGF-21 were combined to analyze the severity and sensi-
tivity for MDs, however, the severity and sensitivity in
MDs were lower in combination than only GDF-15
(data not shown). Furthermore, the patients’ number was
too small to evaluate the severity and sensitivity.
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The mechanism of elevation of GDF-15 is not clear
in MDs patients. ATF4 is a master regulator of upstream
of stress signals.20 GDF-15 was upregulated by ATF4 in
mouse embryonic fibroblast.21 FGF-21 was also induced
by ATF4 in mouse.22–24 We revealed that GDF-15 and
FGF-21 were elevated in MDs compared to controls, and
both GDF-15 and FGF-21 levels were correlated with
MDs. Therefore, we suggested that the mechanism of ele-
vation of GDF-15 in MDs is derived from ATF4 signal-
ing and occurred from various stresses during
mitochondrial dysfunctions. More investigations are
requested to clarify what kinds of interactions exist in the
disease condition such as HF, kidney disease, and cancers.
In conclusion, our data suggest that the measure-
ment of GDF-15 in combination with FGF-21 by
ELISA serves as the most useful first-line test in patients
with suspected MDs to prioritize patients for muscle
biopsy. Using new biomarkers, we may be able to diag-
nose MDs at a nonspecialist hospital and reduce the
unnecessary invasive biopsy procedures in children and
adults.
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